Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Neurological Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for SEMA5A drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SEMA5A ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View SEMA5A Products |
| Gene Delivery | SEMA5A Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View SEMA5A Products |
| Benchmark Ab | Anti-SEMA5A (Sequence of Benchmark) Recombinant positive control. |
View SEMA5A Products |
| Validator | SEMA5A siRNA Set For knockdown verification. |
View SEMA5A Products |
| Related Target A | PLXNB3 Primary high-affinity receptor for SEMA5A signaling |
View PLXNB3 Products |
| Related Target B | MET Co-receptor involved in SEMA5A-mediated tumor invasion |
View MET Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Complex Domain Structure (Sema + TSP type-1 1 & 2) | Full ECD proteins strictly Sequence Verified and HEK293 Expressed (Native Glycosylation) |
| Cross-species cyno/mouse eval | Human/Mouse/Cyno ortholog proteins available with >95% purity |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live SEMA5A R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for SEMA5A therapeutics is intensifying, with major players shifting focus from traditional mAbs to bispecifics and ADCs. As first-generation therapies reach the clinic, the next wave of R&D is targeting the specific modulation of SEMA5A's interactions via its Sema and TSP type-1 domains in tumor microenvironments and neurodevelopmental disorders.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC | Early Stage Biotechs | Solid Tumors (Pancreatic/Gastric) | Internalization Assay (Need high-purity ECD-Fc) |
| Monoclonal Antibody | Academic/Translational | Oncology, Autism Spectrum | Receptor Blocking (Need native-folded PLXNB3/SEMA5A) |
| Bispecific | Preclinical Innovators | Refractory Tumors | Heterodimer Validation (Need Cross-reactive Abs) |